You can write in Portuguese, English, Spanish or French. The search doesn't link to accents or uppercase letters, separates the words (all must appear) and also searches for the equivalent word in other languages: "transplant" finds "transplant" and "trasplante". Searches in the original titles, translated titles into Portuguese, descriptions and abstracts. MielomaAI.
In the last 3 months. From the older news, only the title and link remain in the archive. Those that have about 1 year may no longer be up to date
Looking for words: car t. Saltar para: Recent news (38) · My Hematology (2) · explanations (7) · file (44)
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MDThe American Journal of Managed Care® (AJMC®) (EUA) · 00:11 TratamentosEUAA single chimeric antigen receptor (CAR) T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.
Seminar in Coimbra brings together patients and specialists to discuss multiple myeloma and the role of CAR-T cellsHealthNews (Portugal) · 07:08 Patients and associationsPortugalPT
Referral Before Salvage Therapy Keeps CAR T an Option in MyelomaTargeted Onc (EUA) · 22:08 TratamentosEUADuring a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple MyelomaCancerNetwork (EUA) · 13:13 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss the potential role of cereblon E3 ligase modulators (CELMoDs) following chimeric antigen receptor (CAR) T-cell therapy and in combination with bispecific antibodies for multiple myeloma.
- Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D CandidateGlobeNewswire (Internacional) · 13:53 TratamentosInternacional
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D...
Gilead at Wolfe Healthcare Conference: anito-cel launch in focus By Investing.comInvesting.com India (EUA) · 17:07 TratamentosEUA
High-Risk Multiple Myeloma Linked to Earlier CAR-T Cell FailureEMJ (Reino Unido) · 08:00 TratamentosReino UnidoHigh-risk multiple myeloma features were associated distinct patterns of treatment failure after cilta-cel.
Early Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific AntibodiesOncodaily (Reino Unido) · 08:00 TratamentosReino UnidoEarly Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific Antibodies / Bispecific antibodies, cancer, CAR-T, Headlines,
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple MyelomaCancerNetwork (EUA) · 08:00 Acesso e saúde públicaEUAJoshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Starton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD in Combination with Novel CAR-T Therapy for Multiple MyelomaBusiness Wire (Internacional) · 07:00 TratamentosInternacional
Bharat Biotech's Nucelion, VeGen Bio Target 2028 Launch For India's First Dual-Target CAR-T Therapy For MyelomaETV Bharat (China) · 07:00 TratamentosChinaThe Strategic alliance advances VL-2511, a first-in-class dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma, towards a first-in-India Phase 1/2 trial and targeted 2028 commercialisation.
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed MyelomaTargeted Onc (EUA) · 07:00 Acesso e saúde públicaEUADuring a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
Indian Biotechs Collaborate on Locally Manufactured Multiple Myeloma CAR TGenomeWeb (China) · 07:00 Acesso e saúde públicaChinaThe pair are looking to lower costs and improve access to the China-developed dual-targeting therapy.
VeGen Bio teams up with Nucelion Therapeutics to advance dual-target Myeloma CAR-Tpharma.economictimes.indiatimes.com (China) · 07:00 TratamentosChinaVL-2511 is a first-in-class dual autologous CAR-T therapy for multiple myeloma which simultaneously targets BCMA and CD19. Under the agreement, the contract researcher will advance the drug in a Phase 1/2 trial in India
New CAR-T therapy for multiple myeloma to enter India trials soonThe Federal (China) · 07:00 TratamentosChinaBharat Biotech arm Nucelion and VeGen Bio partner to develop dual-target CAR-T cell therapy, aiming for clinical trials and potential 2028 commercialisation
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaPR Newswire (Internacional) · 07:00 Acesso e saúde públicaInternacional/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner,...
NCCN Guidelines Position CAR T Cells in Early Relapsed Multiple MyelomaCancerNetwork (EUA) · 07:00 Acesso e saúde públicaEUAMatthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early relapsed multiple myeloma.
Updated CARTITUDE-2 Data Support Earlier Cilta-Cel Use in Multiple MyelomaCancerNetwork (EUA) · 07:00 TratamentosEUAAdam D. Cohen, MD, reviews 5-year data from cohort A of CARTITUDE-2 for cilta-cel and how bridging therapy may lower the risk of late neurotoxicity.
Anitocabtagene Autoleucel Shows High Response Rate in Heavily Pretreated Relapsed/Refractory Multiple MyelomaThe ASCO Post (EUA) · 07:00 InvestigaçãoEUAAnitocabtagene autoleucel, an investigational B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, produced responses in all treated patients in a phase I study of heavil...
Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myelomaNature · 07:00 TratamentosExtended follow-up of four patients with multiple myeloma treated with in vivo BCMA CAR-T cells showed limited duration of response in three patients, while one patient had sustained response to 15 months.
- Dr Dhakal on the Investigation of Novel CAR T-Cell Therapy Approaches in MyelomaOncLive (EUA) · 07:00 InvestigaçãoEUA
Cobertura jornalística abrangente e atualizada, reunida a partir de fontes em todo o mundo pelo Google News.
MPE webinar: Long-term outcomes of CAR T-cell therapy in myelomaMyeloma Patients Europe (Europa) · 16:08 TratamentosEuropaChimeric antigen receptor (CAR) T-cell therapy is a treatment that uses genetically modified immune cells (T-cells) to treat myeloma. While clinical studies have demonstrated the strong efficacy of CAR T-cell therapies in this disease, many patients experience side effects that can persist for months or years after tr…
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMMTargeted Onc (EUA) · 07:00 TratamentosEUAPublished phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
IASO Bio’s in vivo BCMA CAR-T posts 90% response rate in first human studyAllSci (China) · 07:00 InvestigaçãoChina
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myelomaPR Newswire (Internacional) · 07:00 TratamentosInternacional/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, announced today new long-term follow-up data from the initial...
CAR-T manufacturing & delivery for multiple myeloma patientsJohnson & Johnson (Internacional) · 07:00 Doentes e associaçõesInternacional
iMMagine-1 vs CARTITUDE-1 MAIC Shows Comparable Efficacy, Improved Safety With Anito-Cel in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 07:00 TratamentosEUAA MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent MyelomaThe New England Journal of Medicine (EUA) · 21:52 InvestigaçãoEUA
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointFierce Biotech (EUA) · 07:00 InvestigaçãoEUA
Ben Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026Oncodaily · 18:05 InvestigaçãoBen Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026 / ASCO, ASH 2026, Ben Derman, cancer, CAR-T, DARA, Daratumumab, Lenalidomide, Mount Sinai,
Next-Generation Multiple Myeloma Therapies Market to ReachopenPR.com · 16:44 TratamentosNovember 16 2026 Multiple myeloma treatment is expanding across antibody combinations CAR T cell therapies and newer immune modifying drugs Recent U S approvals have brought some options into earlier treatment lines while new subcutaneous formulations are changing how antibody ...
Tempest acquires rights to experimental myeloma treatmentRare Cancer News · 16:28 TratamentosTempest Therapeutics has exercised an option to obtain rights to develop and commercialize an experimental treatment for myeloma.
CELMoDs as Holding and Bridging Therapy in Multiple MyelomaCancerNetwork (EUA) · 15:43 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith explore the potential role of cereblon E3 ligase modulators (CELMoDs) as holding and bridging therapies for patients with multiple myeloma preparing for chimeric antigen receptor (CAR) T-cell therapy.
APCL brings together specialists and patients in Coimbra to discuss advances in multiple myelomaNews Farma (Portugal) · 11:39 Patients and associationsPortugalPTThe Portuguese Association Against Leukaemia (APCL) is holding a seminar dedicated to multiple myeloma (MM) on November 21st, between 09:30 and 17:20, at the Conservatório de Música de Coimbra School of Arts. The event brings together patients, caregivers, doctors, and other healthcare professionals, fostering dialogue…
Treatment After Early Relapse and Real-World Evidence in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel discusses treatment strategies for patients with relapsed/refractory multiple myeloma who experience early disease progression following BCMA-directed therapy, including CAR T-cell therapy.
T-Cell Fitness and Treatment Sequencing in Multiple MyelomaCancerNetwork (EUA) · 08:00 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how T-cell fitness may influence treatment sequencing in multiple myeloma, particularly as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies become increasingly important treatment options.
Dr. Rahul Banerjee on the future of myeloma careFred Hutchinson Cancer Center (Reino Unido) · 07:00 TratamentosReino UnidoRahul Banerjee, MD, FACP joins Petros Grivas, MD, PhD to discuss how CAR T cell-therapy and bispecific antibodies are changing myeloma care, ongoing Fred Hutch trials, working with community oncologists, and the team approach behind it all.
Zenbexus PFS Data Suggest Utility In Community Treatment Of Multiple MyelomaScrip (China) · 07:00 TratamentosChinaFollowing approval in August, Bristol Myers Squibb reports Phase III PFS data that may make the oral CELMoD an ideal option for community care centers less suited to administering CAR-T and bispecific antibodies.
Click on an article to open it on the side with the summary. MielomaAI And the link to the source.
New treatment options allow for control of the patient with multiple myeloma.InterviewsMy Hematologia · 5 Sep 2025The article reports a discussion about the treatment of multiple myeloma (MM) led by hematologist Catarina Geraldes from the Coimbra ULSS at a hematology event. Read more →
The "promising" future of Hematology-OncologyInterviewsMy Hematologia · May 4, 2022The hematologist-oncologist, Professor Dr. Joaquín Martinez-Lopes, believes that CAR T cells have a promising future in the treatment of diseases such as lymphoma and myeloma. Read more →
- CAR-T
- Treatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion.
- BCMA
- The protein found on the surface of myeloma cells (B cell maturation antigen). It is the target of CAR-T Carvykti and the bispecific teclistamab and elranatamab.
- T lymphocytes
- White blood cells that attack cancerous cells. These are the ones that myeloma patients and specialists put to work attacking the myeloma, and these are used to manufacture CAR-T.
- Bridging Treatment
- Treatment is given while waiting for the CAR-T (which takes weeks to be manufactured) to keep the disease under control.
- Cytokine release syndrome
- Immune system reaction that can occur with CAR-T and bispecifics: fever, chills, low blood pressure. Almost always mild and treatable; therefore, initial doses are monitored.
- ICANS
- Effect on the brain of CAR-T and bispecifics: confusion, difficulty speaking or writing, drowsiness. Generally resolves, but must be reported promptly.
- Extramedullary Disease
- Multiple myeloma with tumors in organs or soft tissues (skin, liver, lymph nodes, nervous system), in diagnosis or, more frequently, in relapses. How it is managed or treated: Intensive treatment; CAR-T and bispecifics are options in relapse; clinical trials. Risk: High risk. See the film "Types of myeloma" →
Access and public health
- Arcellx is advancing the conversation on its platform and the importance of early access to CAR T cells for patients with multiple myeloma during the Tandem 2026 meetings. ↗ · Business Wire · 21/01/2026
- BH Hospital offers CAR-T cell treatment for patients with multiple myeloma ↗ about 1 year · City Connect · 11/09/2025
- A multiple myeloma patient treated at the 12 of October Hospital with the first commercially available CAR-T in Spain is disease-free seven months later ↗ about 1 year · Madrid Community | · 24/02/2025
- FDA lifts partial suspension of Arcellx’s CAR-T CART-ddBCMA trial in multiple myeloma ↗ 3 years · CGTLive® · 15/08/2023
- Approval of Carvykti becomes the second CAR-T therapy for multiple myeloma ↗ 4 years ago · National Cancer Institute (.gov) · 30/03/2022
- FDA approves BCMA-targeted CAR-T therapy for multiple myeloma ↗ 5 years · National Cancer Institute (.gov) · April 14, 2021
Patients and associations
- The CAR-T from Clínic-IDIBAPS for multiple myeloma is effective in patients with rising disease ↗ 3 years · Clínic Barcelona · 04/07/2023
- Einstein uses CAR-T cells in patients with multiple myeloma ↗ 3 years · Medicine Inc. · 13/12/2022
Research
- First results from the first in vivo CAR-T study in multiple myeloma ↗ · The ASCO Post · February 25, 2026
- ASH: anita-cel strengthens the potential to be the best in class while Kite, from Gilead, prepares the launch. · Fierce Biotech · 12/07/2025
- Phase 1 trial of the CAR-T BCMA NEX-T® CC-98633/BMS-986354 therapy in patients with multiple myeloma who have been previously exposed to three classes of drugs ↗ about 1 year · Nature · 05/02/2025
- Phase 2 registration study of anitocabtagene autoleucel in multiple myeloma relapsed and/or refractory: preliminary results from the iMMagine-1 trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Multiple myeloma: cilta-cel proved to be highly effective in a study in real-world clinical practice ↗ 2 years · ScienceDaily — Multiple Myeloma · 10/04/2024
- Arcellx announced strong and durable responses of the CART-ddBCMA (anito-cel) regimen in the Phase 1 trial in patients with multiple myeloma in relapse or refractory status. 2 years · PR Newswire · 08/12/2023
Other
- Project Information | Anitocabtagene autoleucel for Relapsed or Refractory Multiple Myeloma (ID6549) | Recommendation ↗ about 1 year · NICE website · 09/03/2025
- Anitocabtagene autoleucel provides deep responses in multiple myeloma in relapse/refractory disease. about 1 year · OncLive · 11/12/2024
Treatments
- Waiting for CAR-T cells. Gualter's journey to silence multiple myeloma ↗ · Public · 04/07/2026
- Gilead completes the acquisition of Arcellx and secures the annuity-cell for myeloma ↗ · Rare Cancer News · 05/05/2026
- Gilead Sciences completes the acquisition of Arcellx ahead of the potential launch of anito-cel ↗ · Business Wire · 28/04/2026
- Clinic-IDIBAPS optimizes CAR-T academic against multiple myeloma to treat relapses. · Hospital Clínic Barcelona · 20/03/2026
- Gilead-Arcellx Agreement: Up to $7.8 Billion for Anito CAR-T Cell Therapy in Multiple Myeloma · Oncodaily · 26/02/2026
- Gilead acquires Arcellx for $7.8 billion and retains full control of anita-cel ↗ · FirstWord Pharma · 23/02/2026
- Gilead will acquire Arcellx for $7.8 billion and combine its Anktiva with its cancer drugs. · Genetic Engineering and Biotechnology News · February 23, 2026
- Gilead Sciences will acquire Arcellx to maximize the potential of anita-cell. · Business Wire · 23/02/2026
- Kelonia Therapeutics announces the FDA approval of the Investigational New Drug (IND) application for KLN-1010, an in vivo CAR-T therapy for relapsed or refractory multiple myeloma. ↗ · Business Wire · 07/01/2026
- Anito-cel provides durable answers with controlled safety in multiple myeloma in relapse/refractory patients. · OncLive · 15/12/2025
- ASH 2025: ASH 2025: Arcellx and Gilead’s anti-CD38 CAR-T cell therapy challenges the myeloma market in relapse/refractory disease ↗ · Clinical Trials Arena · 12/09/2025
- Anito-cel emerges as a possible new option in multiple myeloma in relapse/refractory ↗ about 1 year · OncLive · 12/11/2025
- Anito-cel maintains sustained efficacy in multiple myeloma in relapse/refractory patients ↗ about 1 year · CancerNetwork · 30/09/2025
- A new experimental CAR-T therapy shows high efficacy in multiple myeloma ↗ about 1 year · Clínic Barcelona · 19/09/2025
- Mater Dei will now offer CAR-T treatment for multiple myeloma ↗ about 1 year · Medicine Inc. · 05/09/2025
- Mater Dei innovates in the treatment of multiple myeloma with CAR-T therapy. about 1 year · Health Business · 04/09/2025
- Anito-cel provides lasting answers in multiple myeloma in relapse/refractory patients ↗ about 1 year · OncLive · 14/06/2025
- Anito-cel shows safety and efficacy in multiple myeloma in relapse/refractory patients ↗ about 1 year · OncLive · 06/01/2025
- The safety profile differs from anito-cel (Gilead/Arcellx) compared to Carvykti (J&J/Legend) ↗ about 1 year · BioSpace · 10/12/2024
- ASH: New data from Gilead and Arcellx strengthen its CAR-T approach versus Carvykti in advanced multiple myeloma ↗ 2 years · Fierce Biotech · 11/05/2024
- Safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in clinical practice in multiple myeloma relapsed/refractory: real-world experience with updated follow-up. 2 years · International Myeloma Society · 27/09/2024
- Carvykti, from J&J and Legend, shows that CAR-T can prolong life in multiple myeloma ↗ 2 years · Fierce Pharma · 02/07/2024
- ASCO: After the shine of CAR-T, GSK strengthens the arguments for Blenrep in multiple myeloma ↗ 2 years · Fierce Pharma · 02/06/2024
- Ciltacabtagene autoleucel in multiple myeloma after relapse and refractoriness to lenalidomide after 1 to 3 treatments ↗ 2 years · NICE website · 08/03/2024
- New immunotherapy against multiple myeloma shows greater efficacy in the laboratory than CAR-T, which is already in use ↗ 2 years · National Centre for Oncology Research - NCIO · 14/02/2024
- Cilt-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma 3 years · The New England Journal of Medicine · 05/06/2023
- Researchers find treatment options for patients whose cancer returns after CAR-T ↗ 4 years ago · ScienceDaily — Multiple Myeloma · 04/11/2022
- Treating multiple myeloma with CAR-T cells, an innovative immunotherapy ↗ 7 years · University Hospital of Poitiers Website · 18/10/2019
